Islet Technology Inc., a research company based in St. Paul, Minnesota, has acquired all co-owned rights to patents related to encapsulated cell therapy.
Thirteen of those patents are licensed on an exclusive basis from the University of California. Seven of the 13 were previously co-owned by Metabolex Inc., of Hayward, California. Islet Technology Inc. now has 15 patents for encapsulated cell therapy granted and three more pending in its patent portfolio. Encapsulated cell therapy is a method of islet transplantation that doesn’t require the use of anti-rejection drugs.